Description
Dipyridamole is a non-selective inhibitor of phosphodiesterases (PDEs) that increases levels of cAMP and cGMP; it also inhibits adenosine deaminase. Dipyridamole exhibits vasodilatory, ati-thrombotic, and anti-inflammatory activities. In monocytes, dipyridamole decreases expression of matrix metalloproteinase 9 (MMP9) by inhibiting TNF-α-induced NF-κB activation, degradation of IkBα, and activation of p38 MAPK. Dipyridamole also inhibits vascular stenosis by suppressing proliferation of venous and arterial smooth muscle cells.
References
Massaro M, Scoditti E, Carluccio MA, et al. Dipyridamole decreases inflammatory metalloproteinase-9 expression and release by human monocytes. Thromb Haemost. 2013 Feb;109(2):280-9. PMID: 23238437.
Alberts MJ. Antithrombotic therapy for secondary stroke prevention. Continuum (Minneap Minn). 2011 Dec;17(6 2ndary Stroke Prevention):1255-66. PMID: 22810029.
Zhuplatov SB, Masaki T, Blumenthal DK, et al. Mechanism of dipyridamole's action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin Pharmacol Toxicol. 2006 Dec;99(6):431-9. PMID: 17169124.
